2011
ACR Appropriateness Criteria® Ductal Carcinoma in Situ
Moran MS, Bai HX, Harris EE, Arthur DW, Bailey L, Bellon JR, Carey L, Goyal S, Halyard MY, Horst KC, MacDonald SM, Haffty BG. ACR Appropriateness Criteria® Ductal Carcinoma in Situ. The Breast Journal 2011, 18: 8-15. PMID: 22107336, DOI: 10.1111/j.1524-4741.2011.01197.x.Peer-Reviewed Original ResearchConceptsWhole breast radiationDuctal carcinomaAppropriateness CriteriaMultiple phase III studiesAppropriateness of imagingPhase III studyACR Appropriateness CriteriaExpert panelRadiology Appropriateness CriteriaEvidence-based guidelinesMultidisciplinary expert panelOmission of radiationPartial breast radiationSpecific clinical conditionsCurrent medical literatureNon-invasive tumorsInvasive relapseBreast radiationLimited diseaseIII studyPeer-reviewed journalsLocal recurrenceAppropriate patientsTumor bedClinical guidelines
2009
Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy.
Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Garber J, Merajver S, Balmanya J, Meirovitz A, Domchek S. Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy. Cancer Research 2009, 69: 959-959. DOI: 10.1158/0008-5472.sabcs-09-959.Peer-Reviewed Original ResearchContralateral breast cancerOperable breast cancerBreast conservationBreast cancerLocal therapyBRCA1/2 mutationsDistant failureClinical characteristicsBRCA1/2 carriersLocal failureBC-specific survivalDeleterious BRCA1/2 mutationsLocal treatment optionsInvasive lobular cancerGermline BRCA1/2 mutationsSignificant predictorsSignificant differencesOnly significant predictorAdjuvant chemotherapyBCT patientsOverall survivalContralateral breastLobular cancerLocal recurrenceRandomized trials
2008
Long‐term outcomes and clinicopathologic differences of African‐American versus white patients treated with breast conservation therapy for early‐stage breast cancer
Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG. Long‐term outcomes and clinicopathologic differences of African‐American versus white patients treated with breast conservation therapy for early‐stage breast cancer. Cancer 2008, 113: 2565-2574. PMID: 18816610, DOI: 10.1002/cncr.23881.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, MucinousAdultAntineoplastic AgentsBlack or African AmericanBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCohort StudiesCombined Modality TherapyFemaleFollow-Up StudiesHumansLymph NodesLymphatic MetastasisMastectomyNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapy DosageSurvival RateTreatment OutcomeWhite PeopleConceptsBreast conservation therapyLymph node recurrenceAA patientsWhite patientsAA womenNode recurrenceConservation therapyClinicopathologic differencesEarly-stage breast cancerChemotherapy/radiotherapyEarly-stage diseaseSurgical margin statusLong-term outcomesP53 expression statusBreast recurrenceOverall survivalIndependent predictorsLocal recurrenceLymph nodesMargin statusClinicopathologic featuresDistant metastasisN classificationMore estrogenBreast cancerBcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy
Yang Q, Moran MS, Haffty BG. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Research And Treatment 2008, 115: 343. PMID: 18516673, DOI: 10.1007/s10549-008-0068-4.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerBreast conservation treatmentStage breast cancerBcl-2 expressionBreast cancerIpsilateral breast tumor recurrenceCox proportional hazards modelBreast tumor recurrenceIndependent prognostic factorProgesterone receptor statusOptimal treatment optionsBcl-2Proportional hazards modelBcl-2 antibodyApoptosis-related proteinsBreast recurrenceLocal relapseLocal recurrencePrognostic factorsReceptor statusClinical outcomesPrognostic significanceTreatment optionsTumor recurrencePrimary tumor